|
A new pill called daraxonrasib has shown remarkable promise in treating advanced pancreatic cancer, with tumors stopping growth in nearly all trial participants and becoming undetectable in one in 12 patients. After one year of treatment, 76.6% of patients were alive compared to the typical 40-45% survival rate with chemotherapy alone, representing what doctors call the biggest breakthrough in pancreatic cancer treatment in decades. While researchers emphasize it is not yet a cure, the drug appears to significantly extend survival time and disease control in patients with this typically fatal cancer.
Read Full Article →
← Back to latest